CRISPR gene therapy offers hope for kids with sickle cell disease

NCT ID NCT05329649

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests a single dose of a gene-edited stem cell treatment (CTX001) in 13 children with severe sickle cell disease who cannot take or did not benefit from hydroxyurea. The goal is to see if the treatment can prevent severe pain crises and hospital stays for at least a year. Because this is an early-phase trial, long-term safety and effectiveness are still being evaluated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOGLOBINOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica

    Rome, Italy

  • Levine Children's Hospital - Hematology

    Charlotte, North Carolina, 28203, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • St.Mary's Hospital - Haematology Dept

    London, United Kingdom

  • The Children's Hospital of Philadelphia - Hematology

    Philadelphia, Pennsylvania, 19104, United States

  • TriStar Medical Group Children's Specialists - Pediatric Oncology

    Nashville, Tennessee, 37203, United States

  • University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology

    Düsseldorf, Germany

Conditions

Explore the condition pages connected to this study.